Your browser doesn't support javascript.
loading
Impact of renal impairment on cardiovascular disease mortality after liver transplantation for nonalcoholic steatohepatitis cirrhosis.
VanWagner, Lisa B; Lapin, Brittany; Skaro, Anton I; Lloyd-Jones, Donald M; Rinella, Mary E.
Afiliação
  • VanWagner LB; Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Lapin B; Department of Medicine, Division of Gastroenterology & Hepatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Skaro AI; Northwestern University Transplant Outcomes Research Collaborative, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Lloyd-Jones DM; Northwestern University Transplant Outcomes Research Collaborative, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
  • Rinella ME; Department of Surgery, Division of Organ Transplantation, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.
Liver Int ; 35(12): 2575-83, 2015 Dec.
Article em En | MEDLINE | ID: mdl-25977117
ABSTRACT
BACKGROUND &

AIMS:

Non-alcoholic steatohepatitis (NASH) is an independent risk factor for cardiovascular disease (CVD) morbidity after liver transplantation, but its impact on CVD mortality is unknown. We sought to assess the impact of NASH on CVD mortality after liver transplantation and to predict which NASH recipients are at highest risk of a CVD-related death following a liver transplant.

METHODS:

Using the Organ Procurement and Transplantation Network database, we examined associations between NASH and post-liver transplant CVD mortality, defined as primary cause of death from thromboembolism, arrhythmia, heart failure, myocardial infarction or stroke. A physician panel reviewed cause of death.

RESULTS:

Of 48 360 liver transplants (2/2002-12/2011), 5057 (10.5%) were performed for NASH cirrhosis. NASH recipients were more likely to be older, female, obese, diabetic and have history of renal failure or prior CVD vs. non-NASH (P < 0.001 for all). Although there was no difference in overall all-cause mortality (log-rank P = 0.96), both early (30-day) and long-term CVD-specific mortality was increased among NASH recipients (Odds ratio = 1.30, 95% Confidence interval (CI) 1.02-1.66; Hazard ratio = 1.42, 95% CI 1.07-1.41 respectively). These associations were no longer significant after adjustment for pre-transplant diabetes, renal impairment or CVD. A risk score comprising age ≥55, male sex, diabetes and renal impairment was developed for prediction of post-liver transplant CVD mortality (c-statistic 0.60).

CONCLUSION:

NASH recipients have an increased risk of CVD mortality after liver transplantation explained by a high prevalence of comorbid cardiometabolic risk factors that in aggregate identify those at highest risk of post-transplant CVD mortality.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações Pós-Operatórias / Doenças Cardiovasculares / Transplante de Fígado / Insuficiência Renal / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2015 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Complicações Pós-Operatórias / Doenças Cardiovasculares / Transplante de Fígado / Insuficiência Renal / Hepatopatia Gordurosa não Alcoólica Tipo de estudo: Diagnostic_studies / Etiology_studies / Prevalence_studies / Prognostic_studies / Risk_factors_studies Limite: Female / Humans / Male / Middle aged País como assunto: America do norte Idioma: En Ano de publicação: 2015 Tipo de documento: Article